Logos Capital
VC Fund
San Francisco, United States
Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifyingcompelling investment ideas and uncorrelated-market returns. They combine scientific diligence with their statistical modeling of clinical trials to achieve the highest levels of conviction in each position.
- Total investments:
- 150
- Last investment:
- Lead investor:
- 6%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Logos Capital invests in
Stages Logos Capital invests in
Countries Logos Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Graham Walmsley
|
|||
Arsani William
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 123 (82%)
- Health Care 74 (49%)
- Therapeutics 50 (33%)
- Pharmaceutical 38 (25%)
- Medical 37 (25%)
Stage
- Series B 50 (33%)
- Post-IPO Equity 42 (28%)
- Series C 25 (17%)
- Series A 18 (12%)
- Series D 3 (2%)
Country
- United States 110 (73%)
- China 6 (4%)
- Canada 4 (3%)
- United Kingdom 2 (1%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Graham Walmsley
Co-Founder and Managing Member
|
Co-Founder and Managing Member | Total investments: 10 | Find email | |
|
Arsani William
Managing Partner and Chief Investment Officer
|
Managing Partner and Chief Investment Officer | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Entera Bio
|
Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M / Post-IPO Equity / Jul 27, 2026 | |
Quince Therapeutics
|
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | |
Achieve Life Science
|
Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M / Post-IPO Equity / Apr 16, 2026 | |
OnKure Therapeutics
|
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $150M / Post-IPO Equity / Mar 27, 2026 | |
Pinnacle Medicines
|
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. | $89M / Series B / Mar 26, 2026 | |
Diamyd Medical
|
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product.Diamyd Medical’s shares aretraded on Nasdaq Stockholm First North, ticker DMYD B. | $24.9M / Post-IPO Equity / Mar 23, 2026 | |
Longeveron
|
Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. This is through the testing of allogeneic human Mesenchymal Stem Cells (MSCs) that are derived from the bone marrow of young, healthy donors. The Longeveron-grown Mesenchymal Stem Cell (LMSCs) product is manufactured in Longeveron’scell processing facility located in Miami, Florida. | $30M / Post-IPO Equity / Mar 10, 2026 | |
Sensei Biotherapeutics
|
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery ofmedicines that alter the treatment landscape and contributing value to patients and society.Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA. | $200M / Post-IPO Equity / Feb 18, 2026 | |
Angitia Biopharmaceuticals
|
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $130M / Series D / Feb 05, 2026 | |
Mirador Therapeutics
|
Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases using an integrated discovery and development platform. The company’s Mirador360 engine combines human genetics, multi-modal data, and analytical tools to identify therapeutic targets, support patient stratification, and inform drug design. Itsofferings include research programs and pipeline assets aimed at conditions such as chronic inflammation and tissue fibrosis. Mirador Therapeutics works with scientific and medical stakeholders to advance targeted therapeutic candidates through preclinical and clinical development. | $250M / Series B / Jan 12, 2026 | |
| See all 150 investments → | |||
Co-Investors
Janus Henderson Investors
61 deals together
Surveyor Capital
60 deals together
RA Capital Management
58 deals together
OrbiMed
41 deals together
Biotechnology Value Fund
38 deals together
Vivo Capital
37 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Logos Capital invest in?
Logos Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 150 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Logos Capital?
Public channels for Logos Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Logos Capital?
The team at Logos Capital includes Graham Walmsley (Co-Founder and Managing Member) and Arsani William (Managing Partner and Chief Investment Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
